Orsenix LLC, of Atlanta, said it completed an end-of-phase II meeting with the FDA and reached a general agreement on the key elements of the phase III program to support an NDA filing for ORH-2014, an oral form of arsenic trioxide, for acute promyelocytic leukemia (APL).